Version 1
: Received: 19 April 2024 / Approved: 23 April 2024 / Online: 23 April 2024 (05:06:50 CEST)
How to cite:
Kiarie, I. W.; Hoffka, G.; Laporte, M.; Leyssen, P.; Neyts, J.; Tőzsér, J.; Mahdi, M. Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2. Preprints2024, 2024041491. https://doi.org/10.20944/preprints202404.1491.v1
Kiarie, I. W.; Hoffka, G.; Laporte, M.; Leyssen, P.; Neyts, J.; Tőzsér, J.; Mahdi, M. Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2. Preprints 2024, 2024041491. https://doi.org/10.20944/preprints202404.1491.v1
Kiarie, I. W.; Hoffka, G.; Laporte, M.; Leyssen, P.; Neyts, J.; Tőzsér, J.; Mahdi, M. Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2. Preprints2024, 2024041491. https://doi.org/10.20944/preprints202404.1491.v1
APA Style
Kiarie, I. W., Hoffka, G., Laporte, M., Leyssen, P., Neyts, J., Tőzsér, J., & Mahdi, M. (2024). Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2. Preprints. https://doi.org/10.20944/preprints202404.1491.v1
Chicago/Turabian Style
Kiarie, I. W., József Tőzsér and Mohamed Mahdi. 2024 "Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2" Preprints. https://doi.org/10.20944/preprints202404.1491.v1
Abstract
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life-cycle, including nuclear importation in case of lentiviruses and integration targeting events, hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase, and interestingly, raltegravir also showed modest antiviral activity against the SARS-CoV-2 Omicron variant in antiviral assays carried out in Vero E6 cells.
Keywords
HIV-2; integrase strand transfer inhibitor (INSTIs); HIV; integrase; Lenacapavir; SARs-CoV-2
Subject
Biology and Life Sciences, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.